Analysis: Sun Pharma Advanced Research Company Limited

Growth thesis

SPARC is a clinical-stage biopharma company focused on oncology (MUC1 ADCs, T-cell engagers) and dermatology (SCD-153 for alopecia/vitiligo), with synthetic lethality and SMDC platforms in preclinical stages. Key growth drivers include SCD-153’s Phase 1B alopecia interim data (Q4 2026), SBO-154’s MUC1 ADC MTD determination (Q3 2026), and a $100M+ PRV litigation outcome (Jan 2026). Management has repeatedly missed Parkinson’s/CML timelines and licensing targets but now prioritizes cost-cutting ($10M annual savings) and India-centric trials to extend cash to FY28. The business hinges on SCD-153/SBO-154 proof-of-concept by 2027 and PRV monetisation, with execution risks tied to trial readouts and regulatory outcomes.

Why is Sun Pharma Advanced Research Company Limited stock rising?

• SCD-153 Phase 1B in alopecia areata expects safety and preliminary efficacy data by Q4 2026, followed by a larger Phase 2 trial
• SBO-154 (MUC1-MMAE ADC) Phase 1 dose escalation completed first two cohorts, entering cohort three approaching pharmacologically relevant dose; early efficacy signals expected early next year
• Expect to receive a pediatric rare disease voucher (PRV) from Sezaby subject to appeal expiry; recent transactions valued above $100 million
• Working with Ocuvex to qualify third-party finished product manufacturing sites for PDP-716 to resolve compliance issues and progress toward market
• Tiller Therapeutics (SCO-155 SMDC) completed pre-IND consultation with FDA and is raising priced external seed capital; SPARC eligible for significant equity in Tiller

Research report

companyname: Sun Pharma Advanced Research Company Limited ticker: SPARC sector: Pharmaceuticals – Research and Development SPARC is a clinical-stage biopharmaceutical company that discovers and develops new chemical entities and biologics, then licenses them to pharmaceutical partners for commercialization. It was incorporated in 2006 as a spin-off from Sun Pharmaceutical Industries to focus on innovative research. The company operates R&D centers in India and the US. As of FY 2025, it has 316 ...

Catalysts

margin expansion, regulatory approval, acquisition inorganic

Growth guidance

No guidance

Management consistency

hype man